Characteristic Study ID	Intervention(s) and control(s)	Deaths [n]	Adverse events [n (%)]	Serious adverse events [n (%)]	Left study owing to adverse events [n (%)]	Hospitalisation [n (%)]	Outpatient treatment [n (%)]
Akilen 2010	I1: cinnamon C1: placebo	I1: 0 C1: 0 T: 0	I1: 0 C1: 1 T: 1	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0
Altschuler 2007	I1: cinnamon C1: placebo	I1: 0 C1: 0 T: 0	I1: 2 (3) C1: 2 (3) T: 4 (6)	I1: 1 (1) C1: 0 T: 1 (1)	I1: 2 (3) C1: 2 (3) T: 4 (6)	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0
Blevins 2007	I1: cinnamon C1: placebo	I1: 0 C1: 0 T: 0	‐	‐	‐	‐	‐
Crawford 2009	I1: cinnamon C1: usual care	I1: 0 C1: 0 T: 0	I1: 1 (2) C1: 0 T: 1 (1)	I1: 0 C1: 0 T: 0	I1: 1 (2) C1: 0 T: 1 (1)	‐	‐
Khan 2003	I1‐3: cinnamon 1/3/6 g C1‐3: placebo 2/6/12 cap	‐	‐	‐	‐	‐	‐
Khan 2010	I1: cinnamon C1: placebo	‐	‐	‐	‐	‐	‐
Mang 2006	I1: cinnamon C1: placebo	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	‐	‐
Rosado 2010	I1: cinnamon C1: placebo	I1: 0 C1: 0 T: 0	I1: 0 C1: 1 T: 1	I1: 0 C1: 0 T: 0	I1: 0 C1: 1 T: 1	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0
Suppapitiporn 2006	I1: cinnamon C1: placebo	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0
Vanschoonbeek 2006	I1: cinnamon C1: placebo	‐	‐	‐	‐	‐	‐
Footnotes: "‐" denotes not reported C: control; cap: capsules; I: intervention; T: total.